IN THE SPOTLIGHT

Estrogen Receptor-α36 Mediates EGFR-SGK1 Signaling-Related Erk Activation in Gastric Cancer

Estrogen Receptor-α36 Mediates EGFR-SGK1 Signaling-Related Erk Activation in Gastric Cancer

Drs Lee and Saxena on the Role of PD-L1 as a Biomarker of Osimertinib Response in EGFR-Mutated NSCLC

Drs Lee and Saxena on the Role of PD-L1 as a Biomarker of Osimertinib Response in EGFR-Mutated NSCLC

Variant allele frequency as a predictor of treatment response to osimertinib in EGFR-mutated NSCLC

Variant allele frequency as a predictor of treatment response to osimertinib in EGFR-mutated NSCLC

The Occupational and Environmental Respiratory Exposome as a Potential Modulator of Adaptive Resistance to EGFR and ALK Inhibitors in Non-Small Cell Lung Cancer

The Occupational and Environmental Respiratory Exposome as a Potential Modulator of Adaptive Resistance to EGFR and ALK Inhibitors in Non-Small Cell Lung Cancer

Targeting pancreatic cancer with combined inhibition of EGFR and RAF

Targeting pancreatic cancer with combined inhibition of EGFR and RAF

A Case of Primary EGFR T790M Mutation in Treatment-Naïve Advanced NSCLC: Clinical and Molecular Implications

A Case of Primary EGFR T790M Mutation in Treatment-Naïve Advanced NSCLC: Clinical and Molecular Implications

BDTX and the CNS-Active EGFR Trend: Why C797S Is the Prize

BDTX and the CNS-Active EGFR Trend: Why C797S Is the Prize

奥希替尼联合化疗一线治疗 EGFR/TP53 共突变伴多发转移晚期肺癌:肺部及脑转移病灶快速退缩并获部分缓解_腾讯新闻

奥希替尼联合化疗一线治疗 EGFR/TP53 共突变伴多发转移晚期肺癌:肺部及脑转移病灶快速退缩并获部分缓解_腾讯新闻

AACR 2026 | Abbisko Therapeutics Showcases Six Research Advances Highlighting pan-KRAS, 4th Generation EGFR, and Synthetic Lethality Approaches

AACR 2026 | Abbisko Therapeutics Showcases Six Research Advances Highlighting pan-KRAS, 4th Generation EGFR, and Synthetic Lethality Approaches